• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5056670)   Today's Articles (1321)
For: Olivieri G, Nociti V, Iorio R, Stefanini MC, Losavio FA, Mirabella M, Mariotti P. Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder. Neurol Sci 2015;36:2301-2. [PMID: 26292790 DOI: 10.1007/s10072-015-2368-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2015] [Accepted: 08/12/2015] [Indexed: 01/11/2023]
Number Cited by Other Article(s)
1
Pizzolato Umeton R, Waltz M, Aaen GS, Benson L, Gorman M, Goyal M, Graves JS, Harris Y, Krupp L, Lotze TE, Shukla NM, Mar S, Ness J, Rensel M, Schreiner T, Tillema JM, Roalstad S, Rodriguez M, Rose J, Waubant E, Weinstock-Guttman B, Casper C, Chitnis T. Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder. Neurology 2023;100:e985-e994. [PMID: 36460473 PMCID: PMC9990442 DOI: 10.1212/wnl.0000000000201625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Accepted: 10/12/2022] [Indexed: 12/05/2022]  Open
2
Bruscolini A, La Cava M, Mallone F, Marcelli M, Ralli M, Sagnelli P, Greco A, Lambiase A. Controversies in the management of neuromyelitis optica spectrum disorder. Expert Rev Neurother 2019;19:1127-1133. [DOI: 10.1080/14737175.2019.1648210] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
3
Gao F, Chai B, Gu C, Wu R, Dong T, Yao Y, Zhang Y. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 2019;19:36. [PMID: 30841862 PMCID: PMC6402122 DOI: 10.1186/s12883-019-1261-2] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Accepted: 02/19/2019] [Indexed: 01/06/2023]  Open
4
Collongues N, Ayme-Dietrich E, Monassier L, de Seze J. Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. Drugs 2019;79:125-142. [PMID: 30623348 DOI: 10.1007/s40265-018-1039-7] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
5
Gmuca S, Xiao R, Weiss PF, Waldman AT, Gerber JS. Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder. ACTA ACUST UNITED AC 2018;3. [PMID: 29782625 DOI: 10.1186/s40893-018-0035-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA